MedTrace Logo

Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients

NCT00350792 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2010-10-13

Study results available
· View outcomes & findings →

Summary

A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

pemetrexed

500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles

DRUG

carboplatin

Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles

Sponsors & Collaborators

Principal Investigators

  • 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-11-30
Completion
2009-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350792 on ClinicalTrials.gov